Immune-Mediated Inflammatory Disease Forum

Our Day 1 Daily Highlights podcast for ACR is here!  Tune in now to hear from our IMID Rheumatology Chair, Dr Sofia Ramiro, as she runs through all of the highlights for the 8th November. Listen now! 🎧 imidforum.com/congress/88/ac…

🌟 Highlighted 🌟 10:30am - 12:30pm 0456: LFD-200, an Antibody Drug Conjugate That Selectively Delivers a Glucocorticoid to Immune Cells, has Anti-Inflammatory Activity and was Well Tolerated Without Systemic Side Effects in an Ongoing Phase 1 Study Matthew McClure, MD #ACR2026

🌟 Highlighted 🌟 10:30am - 12:30pm 0468: Subcutaneous Tocilizumab versus Abatacept in Rheumatoid Arthritis with inadequate response to TNFis: results of the SUNSTAR head-to-head, multicentre, open-label, randomised superiority trial Tristan Pascart, MD, PhD #ACR2026

🌟 Highlighted 🌟 10:30am - 12:30pm 0460: Ocadusertib, a Novel Oral Selective Receptor-Interacting Serine/Threonine-Protein Kinase 1 Inhibitor, Demonstrates Target Engagement but Limited Clinical Efficacy in Moderately-to-Severely Active Rheumatoid Arthritis: Results from a Phase 2a Trial Eric Hanson, MD #ACR2026

🌟 Highlighted 🌟 10:30am - 12:30pm 0454: IL-6/TNFα-neutralizing CD19 CAR T-cell therapy in difficult-to-treat rheumatoid arthritis: Long-term follow-up and immune remodeling Zhu Chen, MD #ACR2026

🌟 Highlighted 🌟 10:30am - 12:30pm 0358: Effectiveness of Guselkumab vs Golimumab in Participants with Active Psoriatic Arthritis and Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Interim Results at 6 Months in a Phase 3b, Randomized, Open-Label, Pragmatic Trial Sarah Gillespie, MS #ACR2026

🌟 Highlighted 🌟 10:30am - 12:30pm 0359: Efficacy and Safety of Tildrakizumab in Anti-TNF-Naïve Patients With Active Psoriatic Arthritis: Week 52 Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Philip Mease, MD, MACR #ACR2026

🌟 Highlighted 🌟 10:30am - 12:30pm 0356: Crusekitug Treatment Resulted in Improvements in Clinical and Radiographic Outcomes in Ankylosing Spondylitis: 52-Week Results from Phase 3 Study Yujie Zhu #ACR2026

Tomorrow is the first day of sessions and abstracts at ACR!  Remember, you can listen to our Daily Highlights podcasts every morning with Dr Sofia Ramiro Register now and be the first to know when it goes live! imidforum.com/congress/88/ac…

It's here; ACR begins today!  Whilst sessions kick off tomorrow, you can check out our Preview Podcast and Highlights Brochure, both available now! 📃 imidforum.com/congress/88/ac… 🎧 imidforum.com/congress/88/ac…

Stein Gold et al. evaluated once-daily icotrokinra in adults with moderate-to-severe plaque PsO in the phase III ICONIC-ADVANCE 1 and 2 trials. Dive into the data here: imidforum.com/publications/9…

📑 Our latest #dermatology slide deck and literature highlight are now available on the #IMIDForum! Stay up to date with the newest research and clinical insights. Access them for free today: imidforum.com/literature-rev…

Our latest #CD slide deck and literature highlight are now available on the #IMIDForum! Stay up to date with the newest research and clinical insights. Access them for free today: imidforum.com/publications

Noor et al. assessed whether the benefit of top-down treatment from diagnosis results in modification of the long-term disease course. Read our set of summary slides for free right here ➡️ow.ly/o45A51046as

In adults aged ≥65 years with RA, JAK inhibitors were not associated with a significantly higher risk of VTE than TNFi(s) over 3 years. See the full insights from Ibis et al. here: imidforum.com/publications/9…

Choudhury et al. found that zasocitinib 15 or 30mg QD reduced TYK2- and skin / joint-related biomarkers in patients with active PsA, with changes observed in ACR20 responders but not consistently in nonresponders. ow.ly/Y09B50ZXvqn #IMIDForum

Our latest #RA literature highlights, featuring research by Ibis et al. and Russell et al. are now live on the #IMIDForum. Access these comprehensive slide decks for the latest insights in RA treatment: imidforum.com/literature-rev…

👉 Our November literature search identified 120 new papers in #RA! 👀 View the results by clicking the link below: imidforum.com/resources

Stay informed with our latest #dermatology literature highlights and detailed slide deck. Now available for free on the #IMIDForum: imidforum.com/literature-rev…

Three days to go till ACR begins! ACR will kick off on Friday, with sessions beginning on Sunday 8th November. Make sure to follow us to be the first to know when our Daily Highlights podcasts are available. imidforum.com/congress